Ten years ago it was a commonly held belief in the medical community that fibrosis and cirrhosis were irreversible. Current understanding is that the body resorbs collagen scar tissue if the stimulating trigger of fibrogenesis is removed (ie.: as in Hepatatis C patients after achieving Sustained Viral Response (SVR) due to Standard-Of-Care antiviral therapy; also in recovering alcoholics who improve their fibrosis staging after cessation of alcohol use).
Scientists now know that levels of liver fibrosis or cirrhosis in Hepatitis C patients are the result of a dynamic between two opposing metabolic events: the abnormal Hepatitis C-related manifestation of fibrogenesis (collagen secretion) in the liver vs. the body’s own anti-fibrotic or cirrhosis-reducing mechanisms. If the fibrogenic stimulus is reduced or removed, the body’s own anti-fibrotic mechanisms, which naturally resorbs scar tissue at a somewhat constant rate, may have a positive effect on the net levels of fibrosis or cirrhosis in the liver. Net reduction of fibrosis or cirrhosis levels by the body’s own mechanisms may be a long-term benefit of the amelioration of the clinical manifestations of Hepatitis C by the HepTech Medical Food Protocol.
We invite you to see what the HepTech Comprehensive Medical Food protocol did for HepTech founder Todd Schneider's fibrosis staging (see below). Todd's unique case brought together some of the world's most knowledgable liver specialists to collaborate over years of research and experimentation to refine and produce the HepTech Comprehensive Medical Food Protocol. To read and hear about Todd's remarkable journey from the precipice of dire health consequences to health and recovery through science and research click here.
Generally, there are two methods to measure liver fibrosis/cirrhosis.
Liver Biopsies remain the "gold standard" for measuring fibrosis staging, but it is recommended that biopsies should only be performed every 3-5 years. However, to measure progress of the HepTech Comprehensive Medical Food protocol, fibrosis staging should be determined every six months to measure progress. Therefore we recommend one of the two non-invasive diagnostic techniques listed below, with an initial scoring established early on in the protocol to measure progress.
Fibroscan - In Canada and Europe a non-invasive technique is available using a FibroScan machine (http://www.echosens.com/), which sends a sonic pulse into the liver which measures the reflective time of the pulse in return. This reading correlates with liver stiffness and fibrosis staging. However, this machine has not yet been cleared for use in the US by the FDA, so only patients living in Europe or Canada may have access to this method.
We recommend that a beginning Fibroscan test be done initially on all non-US patients followed by periodic follow-ups to track progress. Progress should be monitored every six months, preferably using the same method for purpose of correlation.
Click here to see a copy of Todd Schneider’s FibroScan readings from the period of 2004 to the present.